title: SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.
abstract: Suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway and generally function as tumor suppressors. The absence of SOCS3 in particular leads to heightened activation of the STAT3 transcription factor, which has a striking ability to promote tumor survival while suppressing antitumor immunity. We report for the first time that genetic deletion of SOCS3, specifically in myeloid cells, significantly enhances tumor growth, which correlates with elevated levels of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment, and diminishes CD8(+) T-cell infiltration in tumors. The importance of MDSCs in promoting tumor growth is documented by reduced tumor growth upon depletion of MDSCs. Furthermore, SOCS3-deficient bone-marrow-derived cells exhibit heightened STAT3 activation and preferentially differentiate into the Gr-1(+)CD11b(+)Ly6G(+) MDSC phenotype. Importantly, we identify G-CSF as a critical factor secreted by the tumor microenvironment that promotes development of MDSCs via a STAT3-dependent pathway. Abrogation of tumor-derived G-CSF reduces the proliferation and accumulation of Gr-1(+)CD11b(+) MDSCs and inhibits tumor growth. These findings highlight the critical function of SOCS3 as a negative regulator of MDSC development and function via inhibition of STAT3 activation.
authors: Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
authors: Hao
authors: H
authors: Yu
authors: Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
authors: Yudong
authors: Y
authors: Liu
authors: Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama.
authors: Braden C
authors: BC
authors: McFarland
authors: Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
authors: Jessy S
authors: JS
authors: Deshane
authors: Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
authors: Douglas R
authors: DR
authors: Hurst
authors: Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama.
authors: Selvarangan
authors: S
authors: Ponnazhagan
authors: Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama. hqin@uab.edu tika@uab.edu.
authors: Etty N
authors: EN
authors: Benveniste
authors: Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, Alabama. hqin@uab.edu tika@uab.edu.
authors: Hongwei
authors: H
authors: Qin
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D022423:Myeloid Cells / Q000276:immunology*; D050796:STAT3 Transcription Factor / Q000235:genetics*; D015398:Signal Transduction / Q000235:genetics*; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology*; D059016:Tumor Microenvironment
chemical_list: D050796:STAT3 Transcription Factor; C491411:Socs3 protein, mouse; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins
references: Cancer Treat Rev. 2012 Nov;38(7):904-10
references: 22651903
references: Immunity. 2004 Feb;20(2):153-65
references: 14975238
references: Cancer Res. 2013 Oct 1;73(19):5892-904
references: 23913828
references: J Immunol. 2012 Oct 1;189(7):3439-48
references: 22925925
references: J Clin Invest. 2011 Jul;121(7):2794-807
references: 21646719
references: J Clin Invest. 2012 Nov;122(11):4094-104
references: 23064360
references: Nat Rev Cancer. 2009 Nov;9(11):798-809
references: 19851315
references: Cancer Res. 2004 Aug 15;64(16):5839-49
references: 15313928
references: PLoS One. 2011;6(11):e27690
references: 22110722
references: Nat Rev Immunol. 2012 Apr;12(4):253-68
references: 22437938
references: Mol Cell Biol. 2014 Oct;34(20):3911-25
references: 25113558
references: Cancer Cell. 2012 Jun 12;21(6):822-35
references: 22698406
references: PLoS One. 2012;7(11):e50874
references: 23226414
references: Cancer Res. 2002 Nov 15;62(22):6659-66
references: 12438264
references: Cancer Res. 2008 Jan 1;68(1):292-300
references: 18172322
references: Cancer Res. 2013 Aug 15;73(16):5288-98
references: 23824741
references: Prostate. 2010 Mar 1;70(4):443-55
references: 19902470
references: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
references: 7724580
references: Cell. 2012 Jul 6;150(1):165-78
references: 22770218
references: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7
references: 19346489
references: J Immunol. 2014 Jan 1;192(1):59-72
references: 24323580
references: J Immunol. 2008 Oct 15;181(8):5791-802
references: 18832739
references: Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5004-9
references: 22411837
references: Cytokine Growth Factor Rev. 2012 Jun;23(3):127-38
references: 22591635
references: J Exp Med. 2008 Sep 29;205(10):2235-49
references: 18809714
references: Nat Rev Cancer. 2012 Apr;12(4):237-51
references: 22437869
references: J Immunol. 2013 Jul 1;191(1):17-23
references: 23794702
references: Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9
references: 25071169
references: Immunity. 2012 Feb 24;36(2):239-50
references: 22342841
references: Nat Rev Cancer. 2008 Aug;8(8):618-31
references: 18633355
references: Onco Targets Ther. 2012;5:119-25
references: 22815644
references: Nat Rev Immunol. 2007 Jun;7(6):454-65
references: 17525754
references: Cancer Res. 2014 Feb 15;74(4):1227-37
references: 24177177
references: Cancer Res. 2009 Sep 15;69(18):7375-84
references: 19738059
references: Urologia. 2012;79 Suppl 19:4-8
references: 22865333
references: J Clin Invest. 2013 Oct;123(10):4464-78
references: 24091328
references: Immunol Cell Biol. 2013 Sep;91(8):493-502
references: 23797066
references: Mol Cancer Res. 2008 May;6(5):675-84
references: 18505913
references: Nat Rev Cancer. 2013 Oct;13(10):739-52
references: 24060865
references: J Immunol. 2002 Aug 1;169(3):1219-27
references: 12133942
references: J Clin Invest. 2013 Apr;123(4):1580-9
references: 23454751
references: Cancer Res. 2014 May 1;74(9):2591-603
references: 24607843
references: Cancer Res. 2007 Jun 15;67(12):5789-97
references: 17575146
references: Prostate. 2011 Feb 15;71(3):318-25
references: 20717995
references: Eur J Immunol. 2013 Jul;43(7):1883-95
references: 23592500
references: Cancer Discov. 2012 Aug;2(8):722-35
references: 22822050
references: Cancer Res. 2013 Mar 15;73(6):1752-63
references: 23328584
references: Immunity. 2012 Apr 20;36(4):542-50
references: 22520847
references: JAKSTAT. 2013 Jul 1;2(3):e24053
references: 24069550